导航与机器人辅助椎弓根螺钉置入在特发性脊柱侧凸后路脊柱融合术中比徒手技术更具成本效益:支付方视角
本研究为回顾性成本分析研究,从公共支付方视角构建马尔可夫决策分析模型,比较机器人辅助导航(RAN)、图像引导术中导航(NAV)与徒手(FH)技术治疗特发性脊柱侧凸的成本效益。
要点
- 与FH相比,RAN的ICUR为每QALY 10672美元,NAV的ICUR为每QALY负108831美元,均低于50000美元的社会支付意愿阈值。
- 在50000美元支付意愿阈值下,RAN并不比NAV更具成本效益(ICUR为每QALY 255518美元)。
- 成本效益可接受性曲线分析显示,在高于50000美元的所有支付意愿阈值下,RAN均为最具成本效益的策略。
核心结论
- NAV和RAN均比FH更具成本效益。
- 支付方应考虑扩大对NAV和RAN的报销覆盖。
研究设计与样本
- 回顾性成本分析研究,证据等级为III级。
- 构建马尔可夫决策分析模型,对特发性脊柱侧凸患者的FH、NAV、RAN进行成本效用分析,并进行概率敏感性分析。
- 健康状态概率、相关报销成本和 quality-adjusted life years(QALYs)均从文献中估算。
- 对每种技术计算增量成本效用比(ICURs)、净成本、增量净货币效益、净货币效益和QALYs。
- 通过将支付意愿阈值在10000美元至250000美元之间变化进行成本效益可接受性(CEA)曲线分析,并通过变化概率、QALYs和成本进行确定性敏感性分析(DSA)。
主要发现
- 与FH技术相比,RAN的ICUR为每QALY 10672美元,NAV的ICUR为每QALY负108831美元,均低于50000美元的社会支付意愿阈值。
- 在50000美元支付意愿阈值下,RAN并不比NAV更具成本效益(ICUR为每QALY 255518美元)。
- CEA显示,在高于50000美元的所有支付意愿阈值下,RAN均为最具成本效益的策略。
- NAV每例患者的平均成本比FH低3610美元(95% CI:3419至3801美元;P < 0.001)。
- RAN每例患者的平均成本比FH高527美元(95% CI:267至786美元;P < 0.001),比NAV高4137美元(95% CI:3953至4320美元;P < 0.001)。
关键数值与推荐
- RAN的ICUR为每QALY 10672美元,NAV的ICUR为每QALY负108831美元,均低于50000美元的社会支付意愿阈值。
- RAN相对于NAV的ICUR为每QALY 255518美元,在50000美元支付意愿阈值下RAN并不比NAV更具成本效益。
- NAV每例患者平均成本比FH低3610美元(95% CI:3419至3801美元;P < 0.001)。
- RAN每例患者平均成本比FH高527美元(95% CI:267至786美元;P < 0.001),比NAV高4137美元(95% CI:3953至4320美元;P < 0.001)。
- DSA显示对小于25%的变量敏感。
临床怎么用
- 支付方应考虑扩大对NAV和RAN的报销覆盖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective cost-analysis study. OBJECTIVE: The primary aim of this study was to determine the cost-effectiveness from a public payer's perspective between RAN, NAV, and FH. BACKGROUND: Robotic-assisted navigation (RAN) and image-guided intraoperative navigation (NAV) are associated with higher pedicle screw placement accuracy and lower complication rates than freehand (FH) technique to treat idiopathic scoliosis. However, RAN and NAV are underutilized and payer coverage remains limited. METHODS: A Markov decision-analysis model for a cost-utility analysis of FH/NAV/RAN for patients with IS was created, and a probability sensitivity analysis was performed. Probabilities of health states, associated reimbursement costs, and quality-adjusted life years (QALYs) were estimated from literature. For each technique, incremental cost-utility ratio (ICURs), net costs, incremental net monetary benefit, net monetary benefit, and QALYs were calculated. Cost-effectiveness acceptability (CEA) curve analysis was performed by varying WTPT between $10,000 and $250,000. Deterministic sensitivity analysis (DSA) was performed by varying probabilities, QALYs, and costs. For cost-effective treatment strategies, cost savings to payers, if present, were calculated over a seven-year horizon. RESULTS: When compared with FH technique, the ICUR of RAN ($10,672/QALY) and NAV (-$108,831/QALY) were below the societal willingness-to-pay threshold (WTPT) of $50,000. RAN was not more cost-effective than NAV (ICUR: $255,518/QALY) at a WTPT of $50,000. However, CEA demonstrated that RAN was the most cost-effective strategy for all WTPTs above $50,000. The mean cost of NAV per patient was lower than FH by $3610 (95% CI: $3419-$3801; P < 0.001). Mean cost of RAN per patient was higher than FH by $527 (95% CI: $267-$786; P < 0.001) and NAV by $4137 (95% CI: $3953-4320; P < 0.001). DSA demonstrated sensitivity to < 25% of variables. CONCLUSIONS: NAV and RAN are both more cost-effective than FH. NAV can save payers $45 million over seven years. Payers should consider increasing reimbursement coverage for NAV and RAN. LEVEL OF EVIDENCE: Level III.
引用
- Umesh A, Nian PP, Lu SL, et al. Navigated and Robotic-Assisted Pedicle Screw Placement Are More Cost-Effective Than Freehand Technique for Posterior Spinal Fusion in Idiopathic Scoliosis: A Payer's Perspective. Spine (Phila Pa 1976). 2025. PMID: 41399946. doi:10.1097/BRS.0000000000005599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。